Mass spectrometry reveals potential of b-lactams as SARS-CoV-2 Mpro inhibitors

Malla, T.R.; Tumber, A.; John, T.; Brewitz, L.; Strain-Damerell, C.; Owen, C.D.; Lukacik, P.; Henry Chan, H.T.; Pratheesh, M.; Salah, E.; Duarte, F.; Yang, H.; Rao, Z.; Walsh, M.A.; Schofield, C.J.

DSpace Home
→
Faculty of Allied Health Sciences
→
Pharmacy
→
View Item

Mass spectrometry reveals potential of b-lactams as SARS-CoV-2 Mpro inhibitors

Malla, T.R.; Tumber, A.; John, T.; Brewitz, L.; Strain-Damerell, C.; Owen, C.D.; Lukacik, P.; Henry Chan, H.T.; Pratheesh, M.; Salah, E.; Duarte, F.; Yang, H.; Rao, Z.; Walsh, M.A.; Schofield, C.J.

URI: http://repo.lib.jfn.ac.lk/ujrr/handle/123456789/11209

Date: 2021

Abstract:

The main viral protease (Mpro) of SARS-CoV-2 is a nucleophilic cysteine hydrolase and a current target for anti-viral chemotherapy. We describe a high-throughput solid phase extraction coupled to mass spectrometry Mpro assay. The results reveal some b-lactams, including penicillin esters, are active site reacting Mpro inhibitors, thus highlighting the potential of acylating agents for Mpro inhibition.

Show full item record